drugset / Trial / NCT00951613

A Study of NK012 in Patients With Relapsed Small Cell Lung Cancer

NCT00951613 ↗

Phase 2 Completed 72 enrolled Nippon Kayaku Co., Ltd.
RandomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether NK012 is safe and effective in the treatment of relapsed small cell lung cancer.

Timeline

Start
2009-07
Primary completion
2012-01
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject 7-ethyl-10-hydroxy Camptothecin Small molecule 18 mg/m2 Intravenous
Subject 7-ethyl-10-hydroxy Camptothecin Small molecule 28 mg/m2 Intravenous